Abstract
Is drug treatment of ventricular premature beats ever justified in situations other than acute myocardial infarction? When is it wiser to accept some VPBs than to prescribe potentially toxic doses of antiarrhythmic agent? Some common clinical situations posing these and similar questions are described.